Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
Primary Industries
- Medical
- Device
- Diagnostic
- Disease
- Delivery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 406
License Grant
Licensor grants to Licensee an option to purchase a license to make, use and sell devices incorporating Licensor's Technology for use in blood glucose measurement applications devices and total hemoglobin measurement applications devices for marketing or other distribution directly to, and only for use in, hospitals. Such license shall be exclusive for the earlier of three (3) years following the date that such devices are ready for sale in such market, or four (4) years from the date that Licensor makes the technology available to Licensee. Thereafter, this license shall be nonexclusive. Such license shall include the right to sell such devices on an OEM basis (excluding companies in glucose monitoring business) to no more than two OEM companies at any one time.
Field of Use
Licensee desires an option to purchase a license to technology developed by LABS for use in blood glucose monitoring applications in the hospital market.
IPSCIO Record ID: 6495
License Grant
The Licensor entered into a Collaboration Agreement with the Licensee. Pursuant to the Agreement, the Licensor and the Licensee agreed to develop jointly and to market an in-hospital continuous blood glucose monitoring system. The Agreement provides the Licensee with an exclusive License under the Company’s intellectual property in the hospital market. The Licensee will be responsible for global sales and marketing, and the Licensor will initially be responsible for manufacturing.
License Property
The automatic glucose monitoring system is indicated for automatic, real-time monitoring and trending of blood glucose concentration in critically ill adults in the hospital environment. The development of a method for continuous glucose monitoring via an indwelling sensor would enable clinicians to be more effective in implementing tight glycemic control and provide for better accuracy in monitoring and controlling patients' blood glucose levels.
Field of Use
The rights granted relate in the hospital market. Specifically for use in the critical care market.
IPSCIO Record ID: 2882
License Grant
The Company assigned all of its patent rights on glucose monitoring technology to the Licensee. In exchange for the use of these patent rights the Company acquired a percentage of interest in Licensee and acquired the right to receive royalty payments on revenues generated by any product developed by Licensee that uses our glucose monitoring technology. The transaction between the two companies is deemed to be an arm's-length transaction.
Field of Use
The glucose biosensor technology involves the measurement and monitoring of glucose levels in diabetes patients. The implanted Glucose Biosensor continuously monitors blood glucose without the need for finger sticks. SYBD's implanted biosensor can be programmed to monitor blood glucose according to a predetermined schedule, thus eliminating problems of patient compliance. The sensor alarms for dangerous, life threatening conditions such as hypoglycemia.
IPSCIO Record ID: 286035
License Grant
Licensee is entering into a licensing agreement to further develop, manufacture and have manufactured and to market, sell and distribute the products in the territory without infringing the Licensors Glucose Monitor Technology.
The Licensor of Ireland shall remain proprietor of the Licensors Glucose Monitor Technology but grants to Licensee for the term a sole and exclusive license in the territory, with the right to grant sublicenses, to research, develop, manufacture, have manufactured for Licensee, import and have imported, use, sell, offer for sale and otherwise commercialize the Glucose Monitor Technology, Licensors interest in the joint improvements in the field and the products.
Licensor grants an exclusive license in the territory solely for use in connection with the sale of the product, for the term to use any Licensor trademark, if any, which relates to the Licensors Glucose Monitor Technology applicable to the product.
This agreement includes a non-exclusive grant back to Licensor from Licensee.
License Property
Licensor has technology in relation to the development and production of monitoring devices and drug delivery devices and processes.
Licensor is knowledgeable in the development of devices and methods for directly or indirectly monitoring the concentration of glucose in a subject and has developed unique monitoring devices and methods.
The patents are for Analyte Controlled Liquid Delivery Device and Analyte Monitor; and, Improved Glucose Monitor.
Field of Use
Field shall mean the direct or indirect monitoring of the concentration of glucose in a subject.
IPSCIO Record ID: 29404
License Grant
The Company and the Licensor entered into a License Agreement, pursuant to which the Licensor granted to the Company a worldwide, royalty free, exclusive License, with a limited right to sub-License, to make, have made, use, sell under and exploit in any way a range of key patents, patent applications and know-how owned by the Licensor, relating to electrochemical sensor technologies in all fields in the area of diabetes and blood glucose management generally, the rights to which are retained by the Licensor.
At the time of execution of the Master Services and Supply Agreement in October 2007, the License Agreement was amended to grant the Company a License to certain new patents outside of such field of use.
Field of Use
Field of use shall mean a.) measurement of analytes for purposes of diagnosing, managing, monitoring, prognosticating, treating, or curing diabetes; b.) measurement of blood coagulation; and c.) measurement for purposes of diagnosing, managing, monitoring, prognosticating, treating, or curing blood coagulopathies excluding the measurement of total hemoglobin.
IPSCIO Record ID: 26981
License Grant
The Licensor grants to LABS an exclusive perpetual, worldwide license to (i) use the Masimo Technology to develop Licensed Applications alone or combined with Masimo Applications and to develop Licensed Devices, (ii) to make, have made, use, and sell Licensed Devices, (iii) to sublicense the Masimo Technology for the development of or for use in Licensed Applications and Licensed Devices, and (iv) to sublicense the use, manufacture and sale of Licensed Devices. Masimo Technology incorporates circuitry and software which, among other things, acquires and detects signals generated by red and infrared LEDs, and which is designed to extract arterial oxygen saturation and pulse rate values from such signals.
License Property
Masimo Applications means use of Masimo Set for Vital Signs Monitoring. SpO(Sub 2), Measurement means noninvasive measurement of arterial oxygen saturation (accounting for at least Hb and HbO(Sub 2), and possibly accounting for HbCO and/or HbMeth), plethysmographic waveforms, and/or pulse rate from neonate, pediatric and adult subjects (excludes fetal measurement and venous oxygen saturation). SpO(Sub 2) Sensor means reusable and disposable standard adult, pediatric and neonatal Sensors for use with making SpO(Sub 2) Measurements. Standard SpO(Sub 2) Sensors currently manufactured by Masimo have the following model number.
Licensed Trademarks means the Masimo Set product designation and word mark(s).
IPSCIO Record ID: 3240
License Grant
The cross-licensing agreement with the Licensee, who is Licensor's development partner, is granting an exclusive, perpetual and worldwide license, with sublicense rights, to use all Masimo SET® owned by the Licensor for the monitoring of non-vital signs measurements and to develop and sell devices incorporating Masimo SET® for monitoring non-vital signs measurements in the Licensee Market.
The Licensor also granted the Licensee a non-exclusive, perpetual and worldwide license, with sublicense rights, to use Masimo SET® for the measurement of vital signs in the Licensee Market.
Pursuant to the Cross-Licensing Agreement, the Licensor has licensed from the Licensee the right to make and distribute products in the Licensor Market that utilize rainbow® technology for the measurement of only carbon monoxide, methemoglobin, fractional arterial oxygen saturation and hemoglobin, which includes hematocrit
License Property
The Licensor invented Masimo Signal Extraction Technology®, or Masimo SET®, which provides the capabilities of Measure-Through Motion and Low Perfusion pulse oximetry to address the primary limitations of conventional pulse oximetry. Pulse oximetry is the noninvasive measurement of the oxygen saturation level of arterial blood, or the blood that delivers oxygen to the body's tissues, and pulse rate.
Rainbow® SET platform utilizing both Masimo SET® and licensed rainbow® technology, includes devices cleared by the U.S. Food and Drug Administration, to noninvasively and continuously monitor multiple measurements that previously required invasive or complicated procedures.
Field of Use
The Licensee Market is defined as any product market in which a product is intended to be used by a patient or pharmacist rather than a professional medical caregiver regardless of the particular location of the sale, including sales to doctors, hospitals, alternate care market professionals or otherwise, provided the product is intended to be recommended, or resold, for use by the patient or pharmacist.
IPSCIO Record ID: 7331
License Grant
The Licensor has entered into a development contract and License Agreement for our prothrombin blood clotting measuring device with the Scottish Licensee.
Under the Agreement with the Licensee, the Licensor will grant an exclusive, worldwide License for the use of technology to produce and market a prothrombin blood clotting measuring device.
License Property
Non-Invasive Blood Analyte Measurement Products
The development contract contributes over $2 million, over an 18-month period, and culminates in the delivery of the initial batch of units for market launch during calendar year 2005.
The prothrombin time test belongs to a group of blood tests that assess the clotting ability of blood. The test is also known as the pro time or PT test.
Field of Use
The monitor is the first in a series of applications that measures the content and characteristics of blood through the use of the Hall Effect, a well-known physics phenomenon that can be used to measure the change in magnetic fields – the spaces in which magnetic forces are detectable; created by magnetostrictive ultrasonic scalers to cause the tips of instruments such as ultrasonic scalers to vibrate.
Prothrombin is used by patients undergoing warfarin/coumadin anticoagulation therapy after a heart attack or stroke to ensure that drug levels are maintained at optimum levels.
Prothrombin blood clotting measuring device is a minimally-invasive, accurate and safe, characteristic measuring device for heart attack and stroke sufferers.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
